Substance / Medication

Silver sulfadiazine

Overview

Active Ingredient
silver sulfadiazine
RxNorm CUI
9793

Indications

Silver sulfadiazine cream, USP 1% is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns.

Labeler: Preferred Pharmaceuticals, Inc.Updated: 2026-02-16T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Silver sulfadiazine cream, USP 1% is contraindicated in patients who are hypersensitive to silver sulfadiazine or any of the other ingredients in the preparation.Because sulfonamide therapy is known to increase the possibility of kernicterus, silver sulfadiazine cream, USP 1% should not be used on p

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

23 trials linked to this intervention

23
Total Trials
1
Recruiting
6
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Silver sulfadiazine therapy for the management of burns.
Iswati Erinda Tri, Handayani Estrin, Subrata Sumarno Adi et al. · Br J Community Nurs · 2025
PMID: 40095932Meta-Analysis
Wound healing in second-degree burns in rats treated with silver sulfadiazine: a systematic review and meta-analysis.
Devi Mohan Vimala, Poornima Velswamy, Sivagnanam Uma Tiruchirapalli · J Wound Care · 2022
PMID: 35404714Meta-Analysis
Treating hard-to-heal ulcers: biocellulose with nanosilver compared with silver sulfadiazine.
Chansanti Orawan, Mongkornwong Atthawit · J Wound Care · 2020
PMID: 33320764RCT
A randomized controlled trial comparing antimicrobial (silver sulfadiazine)-coated ureteral stents with non-coated stents.
El-Nahas Ahmed R, Lachine Mohammed, Elsawy Essam et al. · Scand J Urol · 2018
PMID: 28931344RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Silver sulfadiazine (substance)
SNOMED CT
387112002
UMLS CUI
C0037134
RxNorm CUI
9793
Labeler
Preferred Pharmaceuticals, Inc.

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
23
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.